Ebb & Flow

Other stories have happier endings. Functional proteomics company Hybrigenics rescued cash hungry Semaia in an all-stock acquisition last week. Semaia, which has no products in clinical trials, focuses on signal transduction in cancer. "Semaia had been financed to the tune of about

E...